Compositions and methods for treating joints

Patent metadata

Field	Value
Publication number	US-10532069-B2
Application number	US-201715612267-A
Country	US
Kind code	B2
Filing date	Jun 2, 2017
Priority date	Jan 20, 2015
Publication date	Jan 14, 2020
Grant date	Jan 14, 2020

Abstract

Compositions and methods are disclosed for the treatment of osteoarthritis. The compositions comprising combinations of hyaluronic acid, glucosamine, and chondroitin sulfate, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.

First claim

What is claimed is:

1. A composition for treating a joint, comprising:
an injectable formulation comprising hyaluronic acid (HA), glucosamine, and chondroitin sulfate, and the injectable formulation having a pH in the range of about 3-5.

2. The composition of claim 1 , wherein glucosamine is present in a concentration of about 0.005-54 mg/mL.

3. The composition of claim 1 , wherein chondroitin sulfate is present in a concentration of about 0.005-54 mg/mL.

4. The composition of claim 1 , wherein HA is present in a concentration of about 3.6-36 mg/mL.

5. The composition of claim 1 , wherein glucosamine and chondroitin sulfate are present in a ratio by weight of about 1:1.

6. The composition of claim 1 , further comprising trehalose.

7. The composition of claim 1 , wherein
glucosamine is present in a concentration of about 18-20 mg/mL;
chondroitin sulfate is present in a concentration of about 18-20 mg/mL;
HA is present in a concentration of about 12-17.5 mg/mL;
the pH is in the range of about 3.5-4; and
the osmolality is in the range of about 600-650 mOSM.

8. A method of treating a joint, comprising:
injecting a therapeutically effective amount of a formulation into a joint of a subject,

wherein the formulation comprising hyaluronic acid (HA), glucosamine, and chondroitin sulfate, and having a pH of 3-5.

9. The method of claim 8 , further comprising combining the HA with a mixture of the glucosamine and chondroitin sulfate to form the formulation less than about 30 minutes prior to injection.

10. The method of claim 8 , wherein glucosamine is present in the formulation in the range of about 0.005-54 mg/mL.

11. The method of claim 8 , wherein chondroitin sulfate is present in the formulation in the range of about 0.005-54 mg/mL.

12. The method of claim 8 , wherein HA is present in the formulation in the range of about 3.6-36 mg/mL.

13. The method of claim 8 , wherein glucosamine and chondroitin sulfate are present in the formulation in a ratio of about 1:1.

14. The method of claim 8 , wherein the formulation further comprises trehalose.

15. The method of claim 8 , wherein
glucosamine is present in the formulation in the range of about 18-20 mg/mL;
chondroitin sulfate is present in the formulation in the range of about 18-20 mg/mL;
HA is present in the formulation in the range of about 12-17.5 mg/mL;
the pH is in the range of about 3.5-4; and
the osmolality is in the range of about 600-650 mOSM.

16. A kit for treating a joint, comprising:
hyaluronic acid (HA), and glucosamine and chondroitin sulfate separate from the HA, wherein combining the HA, glucosamine, and chondroitin sulfate forms a formulation having a pH in the range of about 3-5; and
a syringe for injecting the formulation into a joint.

17. The kit of claim 16 , wherein the syringe comprises
a first chamber containing the HA;
a second chamber containing the glucosamine and chondroitin sulfate, and in fluid communication with the first chamber; and
a plunger configured to displace the glucosamine and chondroitin sulfate from the second container into the first container, to combine the HA, glucosamine, and chondroitin sulfate, and form the formulation.

18. The kit of claim 16 , wherein glucosamine has a concentration of about 0.005-54 mg/mL.

19. The kit of claim 16 , wherein chondroitin sulfate has a concentration of about 0.005-54 mg/mL.

20. The kit of claim 16 , wherein HA has a concentration of about 3.6-36 mg/mL.

Assignees

• Depuy Synthes Products Inc

Inventors

• Story Brooks J
• Wadsworth Scott A
• Parrish William R
• Herzberg Uri
• Torres Donna
• Byers Benjamin A
• Hwang Julia
• Su Dongling

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61L2430/24

  for joint reconstruction · CPC title